[Skip to Navigation]
Invited Commentary
July 2018

Comparing Aflibercept Monotherapy With Aflibercept Plus Rescue Photodynamic Therapy in Polypoidal Choroidal Vasculopathy: PLANET or Asteroid?

Author Affiliations
  • 1Charlotte Eye, Ear, Nose, and Throat Associates, Charlotte, North Carolina
JAMA Ophthalmol. 2018;136(7):794-795. doi:10.1001/jamaophthalmol.2018.1799

In this issue, Lee et al1 report the 52-week results of the PLANET study, a randomized clinical trial comparing intravitreal aflibercept (IVA) monotherapy with IVA plus rescue photodynamic therapy (IVA+rPDT) beginning at week 12 following 3 monthly injections of IVA in the treatment of polypoidal choroidal vasculopathy (PCV). In a predominantly Asian sample of patients, mean (SD) Early Treatment Diabetic Retinopathy Study (ETDRS) letter gains at week 52 were 10.7 (11.3) and 10.8 (10.7) letters with IVA monotherapy and IVA+rPDT therapy, respectively, with no difference in number of injections or rates of adverse events.

Add or change institution